JP Morgan Private Wealth Advisors’s Cymabay Therapeutics CBAY Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$158K	Buy	+10,627	New	+$141K	﹤0.01%	1653

Other funds holding CBAY

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Private Wealth Advisors's CBAY Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors opened a new position in Cymabay Therapeutics (CBAY) in Q3 2023: 10,627 shares worth $158K. The stake represents ﹤0.01% of the portfolio and ranks #1653 among its holdings.

189 funds tracked by Wall St. Rank hold CBAY as of Q3 2023.

JP Morgan Private Wealth Advisors held 10,627 shares of Cymabay Therapeutics worth $158K as of Q3 2023.
Cymabay Therapeutics was a new JP Morgan Private Wealth Advisors position in Q3 2023.
Cymabay Therapeutics made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1653 holding.
189 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.